Evaluation of Apelin-13 and Apelin-36 in Women With Recurrent Pregnancy Loss

NCT ID: NCT05205044

Last Updated: 2023-02-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

88 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-23

Study Completion Date

2023-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lower Apelin levels are associated with hypertensive disorders with pregnancy, yet no studies investigated its levels in recurrent pregnancy loss

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Pregnancy Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Recurrent pregnancy loss

Apelin-13, Apelin-36

Intervention Type DIAGNOSTIC_TEST

Serum levels of Apelin-13 and Apelin-36

Healthy

Apelin-13, Apelin-36

Intervention Type DIAGNOSTIC_TEST

Serum levels of Apelin-13 and Apelin-36

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apelin-13, Apelin-36

Serum levels of Apelin-13 and Apelin-36

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pregnant women in first trimester
* negative antiphospholipid markers
* normal karyotype

Exclusion Criteria

* multiple pregnancy
* fetal malformations
* maternal diseases
* smoking or alcohol use
* history of or risk factors for preterm labor
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ain Shams University Maternity Hospital

Cairo, Cairo/القاهرة, Egypt

Site Status

AinShams Maternity Hospital

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MS 672/2021

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.